skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an interview at Biotech Showcase. Second Genome has a proprietary microbiome discovery platform that it is using to develop small molecules, peptide biologics and bacterial strains, with one clinical-stage candidate in the pipeline. The company is working with major pharma partners such as Pfizer Venture Fund and Roche Venture Fund, which were among the investors in a Series B round in Spring 2016 and the company is also looking for new partners to develop microbiome candidates in a broad range of diseases, including gastrointestinal conditions, cancer and the metabolic space.









電話:+81 (0)3 6273 4260